医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

MaveriX Oncology to Present at China Showcase 2020 and Biotech Showcase™ 2020 in San Francisco

2020年01月07日 AM02:26
このエントリーをはてなブックマークに追加


 

PALO ALTO, Calif.

MaveriX Oncology, Inc., a development-stage biotechnology company with a proprietary pipeline of targeted small-molecule chemo-immuno-therapeutics for the treatment of a broad range of solid tumor and hematological malignancies, announces its attendance and presentations at the China Showcase 2020 and Biotech Showcase™ 2020 in San Francisco, California.

Dr. Steven A. Everett, President & CEO, will be presenting the Company technology and investment opportunity at the showcases during the following times:

China Showcase 2020:

Date: Sunday, January 12, 2020

Time: 4.15 PM (PST)

Location: Cyril Magnin III (4th floor), the Parc 55 Hotel

Biotech Showcase 2020:

Date: Tuesday, January 14, 2020

Time: 4.15 PM (PST)

Location: Franciscan B (Ballroom level), Hilton San Francisco Union Square

Dr. Steven A. Everett said “We are grateful to Demy-Colton and the EBD Group for the opportunity to present our Company at the China Showcase 2020 and the Biotech Showcase 2020. These are ideal forums to engage cross-border institutional or private investors and explore strategic partnership opportunities. We encourage interested parties to attend our presentations and/or request one-on-one meetings with our executive team through the conference website and partneringONE® at https://informaconnect.com/biotech-showcase/.”

“We are delighted that MaveriX Oncology, Inc., will be presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime occasion for global life science entrepreneurs and investors to come together to discover the potential for cross-border opportunities that will drive the future of drug discovery.”

ABOUT BIOTECH SHOWCASE

Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year. Now in its 12th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-on-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.

ABOUT MAVERIX ONCOLOGY INC.

MaveriX Oncology, Inc., is a globally orientated biotechnology company focused on the discovery, development, and commercialization of targeted small-molecule cancer chemo-immunotherapies. Our technology approach leverages unexploited insights into cancer and immune cell metabolism within the tumor microenvironment which are common to all cancers. Our novel platform is designed to selectively deliver the tumor cell killing benefits of chemotherapy while stimulating a robust immune response to attack a wide range of cancers. Our experienced team is developing a proprietary pipeline of drug candidates with the goal of bringing new and improved treatments to patients suffering from cancer. For more information about the company visit the website https://www.maverixoncology.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200106005820/en/

CONTACT

Karen Sharma
Communications Representative
of MaveriX
Oncology, Inc.
Managing Director, MacDougall
T: +1(781)
235-3060
E: ksharma@macbiocom.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Genetron Health and InnoCare Team Up In Partnership To Accelerate the Development and Commercialization of Novel Drugs for Cancer Treatment
  • Hot Topics Recap: Coronavirus
  • Japan Ministry of Health, Labor and Welfare Approves Opdivo (nivolumab) for the Treatment of Patients with Unresectable Advanced or Recurrent Esophageal Cancer
  • Harbour BioMed Announces Completion of Phase 1 Study in China of HBM9161, an Anti-FcRn Antibody
  • Meiji Seika Pharma Co., Ltd:支持中国控制新型冠状病毒